Literature DB >> 22230328

Role of connexin 43 in the mechanism of action of alendronate: dissociation of anti-apoptotic and proliferative signaling pathways.

V Lezcano1, T Bellido, L I Plotkin, R Boland, S Morelli.   

Abstract

Bisphosphonates (BPs) inhibit osteocyte and osteoblast apoptosis via opening of connexin (Cx) 43 hemichannels and activating the extracellular signal regulated kinases ERKs. Previously, we hypothesized that intracellular survival signaling is initiated by interaction of BPs with Cx43. However, using whole cell binding assays with [(3)H]-alendronate, herein we demonstrated the presence of saturable, specific and high affinity binding sites in the Cx43-expressing ROS 17/2.8 osteoblastic cells, authentic osteoblasts and MLO-Y4 cells expressing Cx43 or not, as well as in HeLa cells lacking Cx43 expression and ROS 17/2.8 cells pretreated with agents that disassemble Cx channels. In addition, both BPs and the PTP inhibitor Na(3)VO(4) increased proliferation of cells expressing Cx43 or not. Furthermore, although BPs are internalized and inhibit intracellular enzymes in osteoclasts, whether the drugs penetrate non-resorptive bone cells is not known. To clarify this, we evaluated the osteoblastic uptake of AF-ALN, a fluorescently labeled analog of alendronate. AF-ALN was rapidly internalized in cells expressing Cx43 or not indicating that this process is not mediated via Cx43 hemichannels. Altogether, these findings suggest that although required for triggering intracellular survival signaling by BPs, Cx43 is dispensable for cellular BP binding, its uptake, as well as the proliferative effects of these agents.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22230328      PMCID: PMC3804299          DOI: 10.1016/j.abb.2011.12.022

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  27 in total

1.  Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates.

Authors:  J E Dunford; K Thompson; F P Coxon; S P Luckman; F M Hahn; C D Poulter; F H Ebetino; M J Rogers
Journal:  J Pharmacol Exp Ther       Date:  2001-02       Impact factor: 4.030

Review 2.  Novel actions of bisphosphonates in bone: preservation of osteoblast and osteocyte viability.

Authors:  Teresita Bellido; Lilian I Plotkin
Journal:  Bone       Date:  2010-08-18       Impact factor: 4.398

3.  Dissociation of the pro-apoptotic effects of bisphosphonates on osteoclasts from their anti-apoptotic effects on osteoblasts/osteocytes with novel analogs.

Authors:  Lilian I Plotkin; Stavros C Manolagas; Teresita Bellido
Journal:  Bone       Date:  2006-04-19       Impact factor: 4.398

Review 4.  Bisphosphonates: from bench to bedside.

Authors:  R Graham G Russell
Journal:  Ann N Y Acad Sci       Date:  2006-04       Impact factor: 5.691

5.  Activation of the PI3K/Akt signaling pathway through P2Y₂ receptors by extracellular ATP is involved in osteoblastic cell proliferation.

Authors:  Sebastián Katz; Victoria Ayala; Graciela Santillán; Ricardo Boland
Journal:  Arch Biochem Biophys       Date:  2011-07-06       Impact factor: 4.013

6.  Extracellular signal-regulated kinases and calcium channels are involved in the proliferative effect of bisphosphonates on osteoblastic cells in vitro.

Authors:  I Mathov; L I Plotkin; C L Sgarlata; J Leoni; T Bellido
Journal:  J Bone Miner Res       Date:  2001-11       Impact factor: 6.741

7.  Protein phosphatases: possible bisphosphonate binding sites mediating stimulation of osteoblast proliferation.

Authors:  Susana Morelli; Paola Scodelaro Bilbao; Sebastian Katz; Virginia Lezcano; Emilio Roldán; Ricardo Boland; Graciela Santillan
Journal:  Arch Biochem Biophys       Date:  2010-12-15       Impact factor: 4.013

8.  Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin.

Authors:  L I Plotkin; R S Weinstein; A M Parfitt; P K Roberson; S C Manolagas; T Bellido
Journal:  J Clin Invest       Date:  1999-11       Impact factor: 14.808

9.  Expression and localisation of the pyrophosphate transporter, ANK, in murine kidney cells.

Authors:  Georgina Carr; John A Sayer; Nicholas L Simmons
Journal:  Cell Physiol Biochem       Date:  2007

Review 10.  Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy.

Authors:  R G G Russell; N B Watts; F H Ebetino; M J Rogers
Journal:  Osteoporos Int       Date:  2008-06       Impact factor: 4.507

View more
  12 in total

Review 1.  Beyond gap junctions: Connexin43 and bone cell signaling.

Authors:  Lilian I Plotkin; Teresita Bellido
Journal:  Bone       Date:  2012-10-02       Impact factor: 4.398

2.  In vitro and in vivo studies using non-traditional bisphosphonates.

Authors:  Lilian I Plotkin; Sonja Buvinic; Julián Balanta-Melo
Journal:  Bone       Date:  2020-02-26       Impact factor: 4.398

Review 3.  Molecular mechanisms of osteoblast/osteocyte regulation by connexin43.

Authors:  Joseph P Stains; Marcus P Watkins; Susan K Grimston; Carla Hebert; Roberto Civitelli
Journal:  Calcif Tissue Int       Date:  2013-06-11       Impact factor: 4.333

4.  Osteoblastic protein tyrosine phosphatases inhibition and connexin 43 phosphorylation by alendronate.

Authors:  V Lezcano; T Bellido; L I Plotkin; R Boland; S Morelli
Journal:  Exp Cell Res       Date:  2014-03-31       Impact factor: 3.905

5.  Comparative Meta-Analysis of Transcriptomics Data during Cellular Senescence and In Vivo Tissue Ageing.

Authors:  Konstantinos Voutetakis; Aristotelis Chatziioannou; Efstathios S Gonos; Ioannis P Trougakos
Journal:  Oxid Med Cell Longev       Date:  2015-04-21       Impact factor: 6.543

Review 6.  Basic research and clinical applications of bisphosphonates in bone disease: what have we learned over the last 40 years?

Authors:  Xiao-Long Xu; Wen-Long Gou; Ai-Yuan Wang; Yu Wang; Quan-Yi Guo; Qiang Lu; Shi-Bi Lu; Jiang Peng
Journal:  J Transl Med       Date:  2013-12-11       Impact factor: 5.531

7.  Avenanthramides Prevent Osteoblast and Osteocyte Apoptosis and Induce Osteoclast Apoptosis in Vitro in an Nrf2-Independent Manner.

Authors:  Gretel G Pellegrini; Cynthya C Morales; Taylor C Wallace; Lilian I Plotkin; Teresita Bellido
Journal:  Nutrients       Date:  2016-07-11       Impact factor: 5.717

8.  Alendronate Can Improve Bone Alterations in Experimental Diabetes by Preventing Antiosteogenic, Antichondrogenic, and Proadipocytic Effects of AGEs on Bone Marrow Progenitor Cells.

Authors:  Sara Rocío Chuguransky; Ana María Cortizo; Antonio Desmond McCarthy
Journal:  Biomed Res Int       Date:  2016-10-20       Impact factor: 3.411

9.  Osteocyte Alterations Induce Osteoclastogenesis in an In Vitro Model of Gaucher Disease.

Authors:  Constanza Bondar; Maximiliano Ormazabal; Andrea Crivaro; Malena Ferreyra-Compagnucci; María Victoria Delpino; Paula Adriana Rozenfeld; Juan Marcos Mucci
Journal:  Int J Mol Sci       Date:  2017-01-13       Impact factor: 5.923

Review 10.  Connexin 43 hemichannels and intracellular signaling in bone cells.

Authors:  Lilian I Plotkin
Journal:  Front Physiol       Date:  2014-04-04       Impact factor: 4.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.